Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective

IF 7.4 1区 医学 Q1 CLINICAL NEUROLOGY Movement Disorders Pub Date : 2024-09-02 DOI:10.1002/mds.29995
Anke Wijers MD, Anirudhan Ravi MSc, Silvia M.A.A. Evers PhD, Gerrit Tissingh MD, PhD, Ghislaine A.P.G. van Mastrigt PhD
{"title":"Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective","authors":"Anke Wijers MD,&nbsp;Anirudhan Ravi MSc,&nbsp;Silvia M.A.A. Evers PhD,&nbsp;Gerrit Tissingh MD, PhD,&nbsp;Ghislaine A.P.G. van Mastrigt PhD","doi":"10.1002/mds.29995","DOIUrl":null,"url":null,"abstract":"<p>Previous reviews on the cost of illness (COI) of Parkinson's disease (PD) have often focused on health-care costs due to PD, underestimating its effects on other sectors. This systematic review determines the COI of PD from a societal perspective. The protocol was registered in PROSPERO (ID: CRD42023428937). Embase, Medline, and EconLit were searched up to October 12, 2023, for studies determining the COI of PD from a societal perspective. From 2812 abstracts, 17 studies were included. The COI of PD averaged €20,911.37 per patient per year, increasing to almost €100,000 in the most severely affected patients. Health-care costs accounted for 46.1% of total costs, followed by productivity loss (37.4%) and costs to patient and family (16.4%). The COI of PD strongly varied between different geographical regions, with costs in North America 3.6 times higher compared to Asia. This study is the first to identify the relative importance of different cost items. Most important were reduced employment, government benefits, informal care, medication, nursing homes, and hospital admission. There was strong variety in the cost items that were included, with 55.2% of cost items measured in fewer than half of articles. Our review shows that PD-COI is high and appears in various cost sectors, with strong variety in the cost items included in different studies. Therefore, a guideline for the measurement of COI in PD should be developed to harmonize this. This article provides a first step toward the development of such a tool by identifying which cost items are most relevant. © 2024 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"39 11","pages":"1938-1951"},"PeriodicalIF":7.4000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.29995","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mds.29995","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Previous reviews on the cost of illness (COI) of Parkinson's disease (PD) have often focused on health-care costs due to PD, underestimating its effects on other sectors. This systematic review determines the COI of PD from a societal perspective. The protocol was registered in PROSPERO (ID: CRD42023428937). Embase, Medline, and EconLit were searched up to October 12, 2023, for studies determining the COI of PD from a societal perspective. From 2812 abstracts, 17 studies were included. The COI of PD averaged €20,911.37 per patient per year, increasing to almost €100,000 in the most severely affected patients. Health-care costs accounted for 46.1% of total costs, followed by productivity loss (37.4%) and costs to patient and family (16.4%). The COI of PD strongly varied between different geographical regions, with costs in North America 3.6 times higher compared to Asia. This study is the first to identify the relative importance of different cost items. Most important were reduced employment, government benefits, informal care, medication, nursing homes, and hospital admission. There was strong variety in the cost items that were included, with 55.2% of cost items measured in fewer than half of articles. Our review shows that PD-COI is high and appears in various cost sectors, with strong variety in the cost items included in different studies. Therefore, a guideline for the measurement of COI in PD should be developed to harmonize this. This article provides a first step toward the development of such a tool by identifying which cost items are most relevant. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从社会角度系统回顾帕金森病的疾病成本。
以往有关帕金森病(PD)疾病成本(COI)的综述通常侧重于帕金森病导致的医疗成本,而低估了其对其他领域的影响。本系统性综述从社会角度确定帕金森病的疾病成本(COI)。该研究方案已在 PROSPERO(ID:CRD42023428937)上注册。截至 2023 年 10 月 12 日,我们在 Embase、Medline 和 EconLit 上检索了从社会角度确定脊髓灰质炎 COI 的研究。从 2812 份摘要中,共纳入了 17 项研究。每位帕金森病患者每年的平均 COI 为 20,911.37 欧元,病情最严重的患者的 COI 将近 10 万欧元。医疗成本占总成本的 46.1%,其次是生产力损失(37.4%)和患者及家庭成本(16.4%)。PD的COI在不同地理区域之间存在很大差异,北美的成本是亚洲的3.6倍。这项研究首次确定了不同费用项目的相对重要性。其中最重要的是就业减少、政府福利、非正规护理、药物治疗、疗养院和住院。纳入的成本项目种类繁多,55.2% 的成本项目在不到一半的文章中进行了衡量。我们的研究结果表明,PD-COI 的发生率很高,而且出现在不同的成本领域,不同研究中包含的成本项目差异很大。因此,应制定一个衡量腹膜透析中 COI 的指南,以统一衡量标准。本文通过确定哪些成本项目最为相关,为开发此类工具迈出了第一步。© 2024 The Author(s).运动障碍》由 Wiley Periodicals LLC 代表国际帕金森和运动障碍协会出版。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Movement Disorders
Movement Disorders 医学-临床神经学
CiteScore
13.30
自引率
8.10%
发文量
371
审稿时长
12 months
期刊介绍: Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.
期刊最新文献
Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial. Omaveloxolone for the Treatment of Friedreich Ataxia: Efficacy, Safety, and Future Perspectives. Skin Inflammatory Reactions in Patients with Continuous Subcutaneous Injection of Foslevodopa-Foscarbidopa Hydrate: Histopathology. Stimulation-Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep. 18F-Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1